Columnists
Tipsheet
Cartoons
Podcasts
Newsletters
Sections
Podcasts
Townhall TV
Election
Capitol Voices
Entertainment
Radio News
Live Blog
Topics
Sites
Hot Air
PJ Media
Bearing Arms
Twitchy
RedState
JOIN VIP
LOGIN
MY ACCOUNT
Account Settings
Newsletter Subscriptions
Log Out
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Respirerx Pharmaceuticals Inc
(OP:
RSPI
)
0.0012
-0.0003 (-20.00%)
Streaming Delayed Price
Updated: 1:05 PM EDT, Jul 12, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
23,258,250
Open
0.0014
Bid (Size)
N/A (0)
Ask (Size)
N/A (0)
Prev. Close
0.0015
Today's Range
0.0012 - 0.0015
52wk Range
0.0006 - 0.0069
Shares Outstanding
N/A
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Stocks Under 1¢: June 2024 Gains, July 2024 Watchlist SMCE, SPZI, RSPI, HALB, BIEI, RJDG
July 03, 2024
Via
AB Newswire
RespireRx Transferes Its Pharmaceutical Cannabinoid Program To ResolutionRx
August 09, 2023
RespireRx Pharmaceuticals Inc. (OTCPK:RSPI), focused on the discovery and development of treatments to combat diseases caused by disruption of neuronal signaling, and ResolutionRx Ltd, an unlisted...
Via
Benzinga
Performance
YTD
+33.33%
+33.33%
1 Month
-52.00%
-52.00%
3 Month
+33.33%
+33.33%
6 Month
-20.00%
-20.00%
1 Year
-29.41%
-29.41%
More News
Read More
RespireRx Pharmaceuticals Inc. Enters a Collaboration With National Institute for Neurological Disorders and Stroke to Advance its Lead GABAkine Toward Clinical Development
December 05, 2022
From
RespireRX Pharmaceuticals Inc.
Via
GlobeNewswire
RespireRx Signs LOI With Australian CRO For Dronabinol Development For Obstructive Sleep Apnea
November 17, 2022
Via
Benzinga
RespireRx Pharmaceuticals Inc. Announces Entry into Letter of Intent with Australian Headquartered CRO for Dronabinol Development for Obstructive Sleep Apnea
November 17, 2022
From
RespireRX Pharmaceuticals Inc.
Via
GlobeNewswire
RespireRx Pharmaceuticals Inc. Announces that Jeff Margolis, the Company’s CFO is presenting at the Investor Summit Q4
November 10, 2022
From
RespireRX Pharmaceuticals Inc.
Via
GlobeNewswire
RespireRx Pharmaceuticals Inc. Announces that Dr. Arnold Lippa Is an Invited Speaker at the 5th Meridian Drug Discovery Summit
November 07, 2022
From
RespireRX Pharmaceuticals Inc.
Via
GlobeNewswire
RespireRx Pharmaceuticals Files Patent: Claims To Improve Solubility & Bioavailability Of Cannabinoids
March 24, 2022
Via
Benzinga
Epigenetics, Psychedelics and Stem Cell Therapy are Topics of the Life Sciences Virtual Investor Conference Launching This Thursday
December 14, 2021
Via
Benzinga
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.